Chromosomal aberrations in multiple myeloma: clinical outcome and response to bortezomib

Abstract

Multiple myeloma (MM) is a heterogeneous disease, for which an understanding of the prognostic and predictive value of chromosomal aberrations is necessary to prescribe the most appropriate therapy. We analyzed the frequency of del(17p13), del(13q14), t(11;14) and t(4;14) in 110 Turkish patients with MM bone marrow aspiration samples. Interphase-fluorescent in situ hybridization were applied to all cases using florescent-labeled probes which were TP 53 /CEP 17 (Vysis, Abbott Global, US) used for 17p13 deletions, LSI 13 (RB 1 ) (Vysis, Abbott Global) used for 13q14 deletions, LSI IgH/CCDN 1 and LSI IgH/FGFR 3 (Vysis, Abbott Global) used to detect t(11;14)(q13;q32) and t(4;14)(p16;q32) translocations, respectively. We studied the clinical effects of bortezomib in 67 patients who were eligible for follow-up. Eighty patients (72.7%) had at least one chromosomal aberration. The most frequently observed aberration was del(17p13) (48.2%), followed by del(13q14) (40.9%), t(11;14) (16.4%), and t(4;14) (11.8%). The results suggest that bortezomib-containing regimens may have beneficial effects on the clinical outcome of patients with del(17p13) and del(13q14).